METHOD OF TREATING LIVER AFFECTION IN LEPROSY PATIENTS Russian patent published in 2011 - IPC A61K31/18 A61K31/496 A61K31/7076 A61P31/08 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to leprology, and can be applied for etiopathogenetic treatment of liver affection in leprosy patients. For this purpose simultaneously with specific anti-leprous therapy introduced is hepatoprotector heptral (S-adenozyle-L-methyonine). Specific anti-leprous therapy includes course introduction of dapson in dose 100 mg daily and riphampicine in dose 600 mg 1 time per month during 6 months with following interval in 1 month. Heptral is introduced in dose 400 mg twice per day in the morning and at lunch time perorally during two weeks.

EFFECT: claimed combined simultaneous introduction of medications in said regimen provides etiotropic and pathogenetic impact on disease, making it possible to realise correction of functional liver malfunctions, as well as to provide adequate protection from action of damaging factors.

4 ex